Modern pharmacotherapy of type 2 diabetes mellitus: focus on empagliflozin


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the current practice, the treatment of type 2 diabetes should be aimed at achieving glycemic control, and the effect on other risk factors for diseases of the cardiovascular system: increased body weight, hypertension, hypoglycemia. Jardins is the first effective hypoglycemic drug of the new generation, which reduces the risk of mortality from cardiovascular disease in patients with type 2 diabetes and concomitant diseases.

Full Text

Restricted Access

About the authors

V. V Skvortsov

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru

B. N Levitan

Astrakhan State Medical University

A. V Sabanov

Volgograd State Medical University, Ministry of Health of Russia

E. M Skvortsova

Volgograd State Medical University, Ministry of Health of Russia

R. Yu Bangarov

Volgograd State Medical University, Ministry of Health of Russia

References

  1. Inzucchi S.E. et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes, Obes Metab. 2020; 22 (4): 631-9. doi: 10.1111/dom.13938
  2. Инструкция по медицинскому применению лекарственного препарата Эмпаглифлозин. Регистрационное удостоверение ЛП-002755 от 2015 г.
  3. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can J. Diabetes. 2016; 40 (3): 193-5. doi: 10.1016/j.jcjd.2016.02.006
  4. Bailey C.l. The challenge of managing coexistent type 2 diabetes and obesity. BMJ. 2011; 342: d1996. doi: 10.1136/bmj.d1996
  5. White W.B., Cannon C.P., Heller S.R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl J. Med. 2013; 369: 1327-35. doi: 10.1056/NEJMoa1305889
  6. Nathan D.M., DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014; 37 (1): 9-16. doi: 10.2337/dc13-2112
  7. Bloomgarden Z.T. Cardiovascular disease in diabetes. Diabetes Care. 2008; 31 (6): 1260-6. doi: 10.2337/dc08-zb06
  8. Grempler R., Thomas L., Eckhardt M. et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT2) inhibitor: oharacterisation and comparison with other SGLT2 inhibitors. Diabetes Obes Metab. 2012; 14 (1): 83-90. doi: 10.1111/j.1463-1326.2011.01517.x
  9. Govan L., Wu 0., Lindsay R. et al. How Do Diabetes Models Measure Up? A Review Of Diabetes Economic Models and ADA Guidelines. JHEOR. 2015; 5 (3): 132-52. doi: 10.36469/9831
  10. Haring H.U. et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes care. 2014; 37 (6): 1650-9. doi: 10.2337/dc13-2105
  11. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 7-изд. Сахарный диабет. 2015; 18 (15): 1-112 doi: 10.14341/DM20151S1-112
  12. Барыкина И.Н., Саласюк А.С., Смирнова В.О. Отчет о научно-исследовательской работе «Фармакоэкономический анализ применения лекарственного препарата Эмпаглифлозин (эмпаглифлозин) при лечении сахарного диабета 2 типа в Российской Федерации». Волгоград, 2016
  13. Амосова М.В., Фадеев В.В. Эмпаглифлозин - новое показание к применению - поворотный момент в лечении сахарного диабета 2-го типа. Медицинский совет. 2017; 3: 38-43 doi: 10.21518/2079-701X-2017-3-38-43
  14. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129-200. DOI: 10.1093/ eurheartj/ehw128
  15. Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 №61-ФЗ Доступно / Available from: http://www. consultant.ru/document/cons_doc_LA W_99350/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies